目标:更多被诊断为乳腺癌(BC)的女性患有肿瘤治疗引起的潮热(HF)。这项以澳大利亚为基础的调查探讨了为什么一些女性会经历更严重或持续的HF,以及特定的人群特征是否可以预测HF的发生。频率,和/或严重性。
方法:在线发布的非概率匿名调查(Register4)和两家澳大利亚医院收集了人口统计学和临床信息。资格是同意澳大利亚女性,18年及以上,原发性BC诊断。分析包括线性和逻辑回归模型。
结果:共分析了324份调查回复。化疗和激素治疗均与HF发生相关(aOR=2.92,95%CI[1.27,6.70],p=0.01;和aOR=7.50,95%CI[3.02,18.62],p<0.001)和组合(aOR=5.98,95%CI[2.61,13.69],p<0.001)。在BC诊断时自我报告的焦虑增加与HF频率和严重程度评分显著相关(aCO=0.71,95%CI[0.31,1.12],p=0.001;aCO=0.44,95%CI[0.33,0.55],p<0.001)。绝经后女性的HF严重程度和频率评分明显低于绝经前女性(aCO=-0.93,95%CI[-1.62,-0.25],p=0.008;aCO=-2.62,95%CI[-5.14,-0.11],p=0.041)。
结论:接受化疗和/或激素治疗和绝经前或经历焦虑和/或压力升高的BC患者可能会经历更严重的肿瘤治疗相关的HFS。
结论:HFs继续跨越BC治疗轨迹,女性>5年生存率仍报告生命影响,与绝经后女性相比,在BC诊断时绝经前女性经历严重和更频繁的肿瘤治疗诱发的HFs的风险更高。高危妇女需要有关减轻HF潜在生活影响并保持治疗依从性的方法的信息。
OBJECTIVE: More women diagnosed with breast cancer (BC) are living with oncology treatment-induced hot flushes (HFs). This Australian-based survey explores why some women experience more severe or ongoing HF and whether specific population characteristics are predictive of HF occurrence, frequency, and/or severity.
METHODS: A non-probabilistic anonymous survey distributed online (Register4) and two Australian hospitals collected demographic and clinical information. Eligibility was consenting Australian-based women, 18 years and over, with a primary BC diagnosis. Analysis included linear and logistic regression models.
RESULTS: A total of 324 survey responses were analyzed. Chemotherapy and hormone therapy were each associated with HF occurrence (aOR = 2.92, 95% CI [1.27, 6.70], p = 0.01; and aOR = 7.50, 95% CI [3.02, 18.62], p < 0.001) and in combination (aOR = 5.98, 95% CI [2.61, 13.69], p < 0.001). Increased self-reported anxiety at BC diagnosis was significantly associated with HF frequency and severity scores (aCO = 0.71, 95% CI [0.31, 1.12], p = 0.001; and aCO = 0.44, 95% CI [0.33, 0.55], p < 0.001). Postmenopausal women had significantly lower HF severity and frequency scores than premenopausal women (aCO = -0.93, 95% CI [-1.62, -0.25], p = 0.008; and aCO = -2.62, 95% CI [-5.14, -0.11], p = 0.041).
CONCLUSIONS: Women with BC receiving chemotherapy and/or hormone therapy and premenopausal or experiencing elevated anxiety and/or stress will likely experience more severe oncology treatment-related HFs.
CONCLUSIONS: HFs continue across the BC treatment trajectory with women >5-year survivorship still reporting life impacts, with premenopausal women at the time of BC diagnosis at higher risk of experiencing severe and more frequent oncology treatment-induced HFs than postmenopausal women. Women at high risk require information on methods to moderate HF potential life impacts and maintain treatment compliance.